These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 37517865)

  • 41. Regulatory landscape for cell therapy--EU view.
    McBlane JW
    Biologicals; 2015 Sep; 43(5):433-6. PubMed ID: 25997566
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Marketing of unproven stem cell-based interventions: A call to action.
    Sipp D; Caulfield T; Kaye J; Barfoot J; Blackburn C; Chan S; De Luca M; Kent A; McCabe C; Munsie M; Sleeboom-Faulkner M; Sugarman J; van Zimmeren E; Zarzeczny A; Rasko JEJ
    Sci Transl Med; 2017 Jul; 9(397):. PubMed ID: 28679655
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The ideal way to design clinical trials and establishment of evidence for human cellular and tissue-based products in Japan.
    Sawa Y
    J Tissue Eng Regen Med; 2019 Jun; 13(6):905-907. PubMed ID: 30938062
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Unproven stem cell-based interventions and achieving a compromise policy among the multiple stakeholders.
    Matthews KR; Iltis AS
    BMC Med Ethics; 2015 Nov; 16(1):75. PubMed ID: 26537611
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Regulated, reliable, and reputable: Protect patients with uniform standards for stem cell treatments.
    Lomax GP; Torres A; Millan MT
    Stem Cells Transl Med; 2020 May; 9(5):547-553. PubMed ID: 32040254
    [TBL] [Abstract][Full Text] [Related]  

  • 46. 19th Annual Meeting of the Safety Pharmacology Society: regulatory and safety perspectives for advanced therapy medicinal products (cellular and gene therapy products).
    Cavero I; Seimetz D; Koziel D; Zimmermann WH; Holzgrefe HH
    Expert Opin Drug Saf; 2020 May; 19(5):553-558. PubMed ID: 32163309
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The committee for advanced therapies' of the European Medicines Agency reflection paper on management of clinical risks deriving from insertional mutagenesis.
    Aiuti A; Cossu G; de Felipe P; Galli MC; Narayanan G; Renner M; Stahlbom A; Schneider CK; Voltz-Girolt C
    Hum Gene Ther Clin Dev; 2013 Jun; 24(2):47-54. PubMed ID: 23862696
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Innovative regenerative medicines in the EU: a better future in evidence?
    Corbett MS; Webster A; Hawkins R; Woolacott N
    BMC Med; 2017 Mar; 15(1):49. PubMed ID: 28270209
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Advanced Therapy medicinal products for autologous chondrocytes and comparison of regulatory systems in target countries.
    Kim J; Park J; Song SY; Kim E
    Regen Ther; 2022 Jun; 20():126-137. PubMed ID: 35582708
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Regulatory Aspects of Cell and Gene Therapy Products: The Japanese Perspective.
    Maruyama Y; Noda S; Okudaira S; Sakurai A; Okura N; Honda F
    Adv Exp Med Biol; 2023; 1430():155-179. PubMed ID: 37526847
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Concise Review: A Comprehensive Analysis of Reported Adverse Events in Patients Receiving Unproven Stem Cell-Based Interventions.
    Bauer G; Elsallab M; Abou-El-Enein M
    Stem Cells Transl Med; 2018 Sep; 7(9):676-685. PubMed ID: 30063299
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Generating comparative evidence on new drugs and devices after approval.
    Cipriani A; Ioannidis JPA; Rothwell PM; Glasziou P; Li T; Hernandez AF; Tomlinson A; Simes J; Naci H
    Lancet; 2020 Mar; 395(10228):998-1010. PubMed ID: 32199487
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Current state of U.S. Food and Drug Administration regulation for cellular and gene therapy products: potential cures on the horizon.
    Mendicino M; Fan Y; Griffin D; Gunter KC; Nichols K
    Cytotherapy; 2019 Jul; 21(7):699-724. PubMed ID: 31196820
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cell-based therapies for retinal diseases: a review of clinical trials and direct to consumer "cell therapy" clinics.
    Hinkle JW; Mahmoudzadeh R; Kuriyan AE
    Stem Cell Res Ther; 2021 Oct; 12(1):538. PubMed ID: 34635174
    [TBL] [Abstract][Full Text] [Related]  

  • 55. An industry survey of implementation strategies for clinical supply chain management of cell and gene therapies.
    Myles L; Church TD
    Cytotherapy; 2022 Mar; 24(3):344-355. PubMed ID: 34750073
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The evolution and ongoing challenge of unproven cell-based interventions.
    Brinsfield TN; Pinson NR; Levine AD
    Stem Cells Transl Med; 2024 Sep; 13(9):851-858. PubMed ID: 39045646
    [TBL] [Abstract][Full Text] [Related]  

  • 57. An assessment of the factors affecting the commercialization of cell-based therapeutics: a systematic review protocol.
    Pettitt D; Arshad Z; Davies B; Smith J; French A; Cole D; Bure K; Dopson S; DiGiusto D; Karp J; Reeve B; Barker R; Holländer G; Brindley D
    Syst Rev; 2017 Jun; 6(1):120. PubMed ID: 28651620
    [TBL] [Abstract][Full Text] [Related]  

  • 58. State-of-the-art knowledge on the regulation of advanced therapy medicinal products.
    Kidpun P; Ruanglertboon W; Chalongsuk R
    Per Med; 2022 May; 19(3):251-261. PubMed ID: 35293224
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Advances and Challenges in the Development of Gene Therapy Medicinal Products for Rare Diseases.
    Bueren JA; Auricchio A
    Hum Gene Ther; 2023 Sep; 34(17-18):763-775. PubMed ID: 37694572
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The Landscape of Cellular and Gene Therapy Products: Authorization, Discontinuations, and Cost.
    Shukla V; Seoane-Vazquez E; Fawaz S; Brown L; Rodriguez-Monguio R
    Hum Gene Ther Clin Dev; 2019 Sep; 30(3):102-113. PubMed ID: 30968714
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.